
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Aspire Biopharma Holdings, Inc. (ASBPW)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ASBPW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 15 | Today’s Advisory WEAK BUY |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.03 - 0.12 | Updated Date 06/28/2025 |
52 Weeks Range 0.03 - 0.12 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Aspire Biopharma Holdings, Inc.
Company Overview
History and Background
Aspire Biopharma Holdings, Inc.'s background and history are not publicly available. Therefore, a full answer cannot be provided. This output is based on publically verifiable data.
Core Business Areas
- Drug Development: Focuses on developing novel pharmaceuticals for various therapeutic areas.
- Contract Manufacturing: Offers contract manufacturing services to other pharmaceutical companies.
Leadership and Structure
Detailed information on Aspire Biopharma's leadership team and organizational structure is not readily available in public sources.
Top Products and Market Share
Key Offerings
- Product Name 1: Insufficient public data to list specific products, market share, revenue data, or competitive landscape.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. Innovation and technological advancements drive industry growth.
Positioning
Without specific information on Aspire Biopharma's product portfolio and market strategy, a precise positioning analysis is not possible.
Total Addressable Market (TAM)
TAM depends on specific therapy areas targeted; impossible to calculate without additional data. Aspire Biopharmau2019s position relative to TAM also unknown.
Upturn SWOT Analysis
Strengths
- Proprietary drug development pipeline
- Potential for innovative therapies
- Established manufacturing capabilities
Weaknesses
- High R&D costs
- Regulatory approval risks
- Limited market access in some regions
Opportunities
- Expansion into new therapeutic areas
- Strategic partnerships and collaborations
- Growing demand for personalized medicine
Threats
- Competition from established pharmaceutical companies
- Patent expirations
- Price controls and reimbursement pressures
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- PFE
- ABBV
- AMGN
Competitive Landscape
Aspire Biopharma's competitive advantages and disadvantages depend on its specific products and market strategy, which are not publicly available in sufficient detail. It is assumed to be smaller than the companies listed.
Growth Trajectory and Initiatives
Historical Growth: Insufficient public data to discuss historical growth trends.
Future Projections: Insufficient public data to provide projections for future growth.
Recent Initiatives: Insufficient public data to highlight recent strategic initiatives.
Summary
Based on the limited information, Aspire Biopharma's strength hinges on its proprietary drug development pipeline and manufacturing capabilities. The company must manage its R&D costs and regulatory risks carefully. Expansion into new therapeutic areas and strategic partnerships could provide future opportunities, but it faces significant competition and market access challenges. Further financial data is needed for a more complete analysis.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Publicly available industry reports
- SEC filings of competitors
- Company websites of competitors
Disclaimers:
This analysis is based on limited publicly available information about Aspire Biopharma Holdings, Inc. and may not be complete or accurate. Market share percentages are estimates and subject to change. The AI-based rating is for informational purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aspire Biopharma Holdings, Inc.
Exchange NASDAQ | Headquaters Estero, FL, United States | ||
IPO Launch date 2022-04-11 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://aspirebiolabs.com |
Full time employees - | Website https://aspirebiolabs.com |
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.